Literature DB >> 1724999

Endothelin.

T F Lüscher1.   

Abstract

Endothelial cells can produce contracting factors; endothelin, a 21-amino acid peptide that can control local vascular tone, is the most potent of these factors. Of the three isoforms of endothelin, endothelial cells appear to release primarily endothelin-1. The peptide is formed from its precursor big endothelin via the activity of the endothelin converting enzyme. The basal production of the peptide is stimulated by epinephrine, angiotensin II, arginine vasopressin, transforming growth factor beta, thrombin, interleukin-1, and the calcium ionophore A23187. In vascular smooth muscle cells, endothelin binds to a specific receptor that activates phospholipase C and leads to the formation of inositol trisphosphate, diacylglycerol, and increased intracellular calcium levels. In certain blood vessels, the endothelin receptor is linked to a voltage-operated calcium channel via a Gi protein. This may explain why calcium antagonists inhibit endothelin-induced contractions only in certain blood vessels. In the human forearm circulation, calcium antagonists of different classes prevent endothelin-induced contractions. In hypertension, the circulating endothelin levels appear to be normal, whereas the vascular sensitivity to the peptide is reduced in most vascular tissues, but normal and enhanced responses have also been reported. In atherosclerosis and other forms of vascular disease, circulating endothelin levels are augmented, a phenomenon that may be related to an increased formation of the peptide induced by modified forms of low-density lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724999

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Pathophysiological significance of plasma endothelin in peripheral circulatory disturbances.

Authors:  H Nakamura; H Nagase; M Yoshida; T Okazawa; A Okada
Journal:  Environ Health Prev Med       Date:  1996-04       Impact factor: 3.674

2.  Change in digital blood flow with simultaneous reduction in plasma endothelin induced by hand-arm vibration.

Authors:  H Nakamura; T Okazawa; H Nagase; M Yoshida; M Ariizumi; A Okada
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

Review 3.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

4.  Inhibition of endothelin-1 receptors improves impaired nitric oxide synthase-dependent dilation of cerebral arterioles in type-1 diabetic rats.

Authors:  Denise M Arrick; William G Mayhan
Journal:  Microcirculation       Date:  2010-08       Impact factor: 2.628

5.  Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing.

Authors:  D C Rockey; J J Chung
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

6.  Endothelin-1 levels in interstitial lung disease patients during sleep.

Authors:  Georgia Trakada; Eugenia Nikolaou; Athanasia Pouli; Maria Tsiamita; Kostas Spiropoulos
Journal:  Sleep Breath       Date:  2003-09       Impact factor: 2.816

7.  Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia.

Authors:  Dima Hamideh; Vimal Raj; Thomas Harrington; Hua Li; Emilio Margolles; Folasade Amole; Monica Garcia-Buitrago; Phillip Ruiz; Gaston Zilleruelo; Ofelia Alvarez
Journal:  Pediatr Nephrol       Date:  2014-06-03       Impact factor: 3.714

Review 8.  Pharmacological aspects of calcium antagonism. Short term and long term benefits.

Authors:  W G Nayler
Journal:  Drugs       Date:  1993       Impact factor: 9.546

9.  Endothelin-1 in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction.

Authors:  Ziemowit Zietkowski; Roman Skiepko; Maria M Tomasiak; Anna Bodzenta-Lukaszyk
Journal:  Respir Res       Date:  2007-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.